Ignite Creation Date:
2025-12-24 @ 4:56 PM
Ignite Modification Date:
2025-12-25 @ 2:38 PM
Study NCT ID:
NCT03428750
Status:
COMPLETED
Last Update Posted:
2020-10-08
First Post:
2018-02-04
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2020-08-24', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D000071697', 'term': 'Cellulite'}], 'ancestors': [{'id': 'D012877', 'term': 'Skin Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'clinicaltrials@endo.com', 'phone': '800-462-3636', 'title': 'Saji Vijayan, MBBS', 'organization': 'Endo Pharmaceuticals'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': 'All (serious and nonserious) AEs, from Day 1 to Day 71', 'description': 'All (serious and nonserious) AEs, whether elicited or observed during study visits or spontaneously reported by the participant, including events that occurred from the time the participant signed the study-specific consent form until completion of or discharge from the study.', 'eventGroups': [{'id': 'EG000', 'title': 'Collagenase Clostridium Histolyticum (CCH)', 'description': 'CCH 0.84 mg/Buttock 1.68 mg Total Dose', 'otherNumAtRisk': 210, 'deathsNumAtRisk': 210, 'otherNumAffected': 166, 'seriousNumAtRisk': 210, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Placebo', 'description': 'Placebo-control', 'otherNumAtRisk': 213, 'deathsNumAtRisk': 213, 'otherNumAffected': 55, 'seriousNumAtRisk': 213, 'deathsNumAffected': 0, 'seriousNumAffected': 1}], 'otherEvents': [{'term': 'Injection site bruising', 'stats': [{'groupId': 'EG000', 'numAtRisk': 210, 'numAffected': 137}, {'groupId': 'EG001', 'numAtRisk': 213, 'numAffected': 42}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.0)'}, {'term': 'Injection site pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 210, 'numAffected': 76}, {'groupId': 'EG001', 'numAtRisk': 213, 'numAffected': 11}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.0)'}, {'term': 'Injection stie nodule', 'stats': [{'groupId': 'EG000', 'numAtRisk': 210, 'numAffected': 38}, {'groupId': 'EG001', 'numAtRisk': 213, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.0)'}, {'term': 'Injection site pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 210, 'numAffected': 29}, {'groupId': 'EG001', 'numAtRisk': 213, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.0)'}, {'term': 'Injection site haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 210, 'numAffected': 25}, {'groupId': 'EG001', 'numAtRisk': 213, 'numAffected': 5}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.0)'}, {'term': 'Injection site mass', 'stats': [{'groupId': 'EG000', 'numAtRisk': 210, 'numAffected': 18}, {'groupId': 'EG001', 'numAtRisk': 213, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.0)'}, {'term': 'Injection site swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 210, 'numAffected': 15}, {'groupId': 'EG001', 'numAtRisk': 213, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.0)'}, {'term': 'Injection site discolouration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 210, 'numAffected': 12}, {'groupId': 'EG001', 'numAtRisk': 213, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.0)'}], 'seriousEvents': [{'term': 'Colitis ischaemic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 210, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 213, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.0)'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': '2-level Composite Responders for the Target Buttock', 'denoms': [{'units': 'Participants', 'counts': [{'value': '210', 'groupId': 'OG000'}, {'value': '213', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Collagenase Clostridium Histolyticum (CCH)', 'description': 'CCH 0.84 mg/Buttock'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Placebo-control'}], 'classes': [{'categories': [{'title': 'Yes: 2-Level Improvement', 'measurements': [{'value': '16', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}, {'title': 'No: 2-Level Improvement', 'measurements': [{'value': '194', 'groupId': 'OG000'}, {'value': '209', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.006', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'CCH 0.84 mg/Buttock versus Placebo', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Adjusted for analysis center'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 71', 'description': 'Number of of 2-level Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) / Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) composite responders in the target buttock at Day 71. CR-PCSS and PR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). A participant who missed one or two assessments of CR-PCSS and PR-PCSS at Day 71 was defined as a non-responder. A 2-level composite responder is defined as a participant with an improvement from baseline of at least 2-levels of severity in the CR-PCSS and an improvement from baseline of at least 2-levels of severity in the PR-PCSS of the target buttock.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.'}, {'type': 'SECONDARY', 'title': '1-level PR-PCSS Responders of the Target Buttock', 'denoms': [{'units': 'Participants', 'counts': [{'value': '210', 'groupId': 'OG000'}, {'value': '213', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Collagenase Clostridium Histolyticum (CCH)', 'description': 'CCH 0.84 mg/Buttock'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Placebo-control'}], 'classes': [{'categories': [{'title': 'Yes', 'measurements': [{'value': '114', 'groupId': 'OG000'}, {'value': '77', 'groupId': 'OG001'}]}, {'title': 'No', 'measurements': [{'value': '96', 'groupId': 'OG000'}, {'value': '136', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'CCH 0.84 mg/Buttock versus Placebo', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Adjusted for analysis center'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 71', 'description': 'Improvement in cellulite severity of the Target Buttock from baseline of at least 1-level of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS). PR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe).', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.'}, {'type': 'SECONDARY', 'title': '2-level PR-PCSS Responders of the Target Buttock', 'denoms': [{'units': 'Participants', 'counts': [{'value': '210', 'groupId': 'OG000'}, {'value': '213', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Collagenase Clostridium Histolyticum (CCH)', 'description': 'CCH 0.84 mg/Buttock'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Placebo-control'}], 'classes': [{'categories': [{'title': 'Yes', 'measurements': [{'value': '51', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}]}, {'title': 'No', 'measurements': [{'value': '159', 'groupId': 'OG000'}, {'value': '187', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.001', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'CCH 0.84 mg/Buttock versus Placebo', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Adjusted for analysis center'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 71', 'description': 'Improvement in cellulite severity of the Target Buttock from baseline of at least 2-level of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS). PR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe).', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.'}, {'type': 'SECONDARY', 'title': '1-level Composite Responders of the Target Buttock', 'denoms': [{'units': 'Participants', 'counts': [{'value': '210', 'groupId': 'OG000'}, {'value': '213', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Collagenase Clostridium Histolyticum (CCH)', 'description': 'CCH 0.84 mg/Buttock'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Placebo-control'}], 'classes': [{'categories': [{'title': 'Yes', 'measurements': [{'value': '78', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}]}, {'title': 'No', 'measurements': [{'value': '132', 'groupId': 'OG000'}, {'value': '175', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'CCH 0.84 mg/Buttock versus Placebo', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Adjusted for analysis center'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 71', 'description': 'Improvement in cellulite severity of the Target Buttock from baseline of at least 1-level of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) / Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS). PR-PCSS and CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe).', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.'}, {'type': 'SECONDARY', 'title': '2-level Composite Responder of the Non-target Buttock', 'denoms': [{'units': 'Participants', 'counts': [{'value': '210', 'groupId': 'OG000'}, {'value': '213', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Collagenase Clostridium Histolyticum (CCH)', 'description': 'CCH 0.84 mg/Buttock'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Placebo-control'}], 'classes': [{'categories': [{'title': 'Yes', 'measurements': [{'value': '16', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}, {'title': 'No', 'measurements': [{'value': '194', 'groupId': 'OG000'}, {'value': '211', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'CCH 0.84 mg/Buttock versus Placebo', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Adjusted for analysis center'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 71', 'description': 'Improvement in cellulite severity of the Non-target Buttock from baseline of at least 2-levels of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) / Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS). PR-PCSS and CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe).', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.'}, {'type': 'SECONDARY', 'title': '1-level SSRS Responders', 'denoms': [{'units': 'Participants', 'counts': [{'value': '210', 'groupId': 'OG000'}, {'value': '213', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Collagenase Clostridium Histolyticum (CCH)', 'description': 'CCH 0.84 mg/Buttock (1.68 mg Total Dose)'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Placebo-control'}], 'classes': [{'categories': [{'measurements': [{'value': '102', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'CCH 0.84 mg/Buttock versus Placebo', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Adjusted for analysis center'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 71', 'description': 'Subject Self-Rating Scale (SSRS) is a measure that assesses participant satisfaction with appearance in association with cellulite on the buttocks using whole numbers on a 7-level scale that ranges from "0" (Extremely Dissatisfied) to "6" (Extremely Satisfied). A 1-level SSRS responder is defined as a participant who is at least slightly satisfied (Slightly Satisfied \\[4\\], Very Satisfied \\[5\\], or Extremely Satisfied \\[6\\]) with the appearance of the cellulite on her buttocks at Day 71.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in PR-CIS Total Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '210', 'groupId': 'OG000'}, {'value': '213', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Collagenase Clostridium Histolyticum (CCH)', 'description': 'CCH 0.84 mg/Buttock (1.68 mg Total Dose)'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Placebo-control'}], 'classes': [{'title': 'Baseline (Day 1)', 'categories': [{'measurements': [{'value': '51.1', 'spread': '8.86', 'groupId': 'OG000'}, {'value': '51.6', 'spread': '9.77', 'groupId': 'OG001'}]}]}, {'title': 'Day 71', 'categories': [{'measurements': [{'value': '40.2', 'spread': '13.27', 'groupId': 'OG000'}, {'value': '45.7', 'spread': '12.93', 'groupId': 'OG001'}]}]}, {'title': 'Change from Baseline', 'categories': [{'measurements': [{'value': '-10.9', 'spread': '12.51', 'groupId': 'OG000'}, {'value': '-5.9', 'spread': '11.62', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'CCH 0.84 mg/Buttock versus Placebo', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'With factors of treatment group and analysis center adjusted for baseline values in the model'}], 'paramType': 'MEAN', 'timeFrame': '71 Days', 'description': 'Patient Reported Cellulite Impact Scale (PR-CIS) is a 6-item static questionnaire, each item is answered by a participant on a 11-level numerical rating scale that ranges from "0" (Not at all) to "10" (Extremely). The PR-CIS total score is the sum of individual item scores and can range from "0" to "60" with higher numbers reflecting a more negative impact from the cellulite. A responder was defined as a participant with a reduction in the PR-CIS total score of at least 12 from baseline at an evaluation time point. A negative change from baseline indicates an improvement in cellulite severity.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.'}, {'type': 'SECONDARY', 'title': '1-level S-GAIS Responders of Target Buttock', 'denoms': [{'units': 'Participants', 'counts': [{'value': '210', 'groupId': 'OG000'}, {'value': '213', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Collagenase Clostridium Histolyticum (CCH)', 'description': 'CCH 0.84 mg/Buttock'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Placebo-control'}], 'classes': [{'categories': [{'measurements': [{'value': '135', 'groupId': 'OG000'}, {'value': '82', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'CCH 0.84 mg/Buttock versus Placebo', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Adjusted for analysis center'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 71', 'description': 'Subject Global Aesthetic Improvement Scale (S-GAIS) is a measure that assesses participant rating of cellulite appearance after treatment. This scale has 7-levels ranging from "+3" (Very Much Improved) to "-3" (Very Much Worse). Responders are defined as participants with at least ≥ 1-level improvement (Improved, Much Improved or Very Much Improved) in S-GAIS assessment of the Target Buttock.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.'}, {'type': 'SECONDARY', 'title': '2-level S-GAIS Responders of Target Buttock', 'denoms': [{'units': 'Participants', 'counts': [{'value': '210', 'groupId': 'OG000'}, {'value': '213', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Collagenase Clostridium Histolyticum (CCH)', 'description': 'CCH 0.84 mg/Buttock'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Placebo-control'}], 'classes': [{'categories': [{'measurements': [{'value': '49', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'CCH 0.84 mg/Buttock versus Placebo', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Adjusted for analysis center'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 71', 'description': 'Subject Global Aesthetic Improvement Scale (S-GAIS) is a measure that assesses participant rating of cellulite appearance after treatment. This scale has 7-levels ranging from "+3" (Very Much Improved) to "-3" (Very Much Worse). Responders are defined as participants with at least ≥ 2-level improvement (Much Improved or Very Much Improved) in S-GAIS assessment of the Target Buttock.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.'}, {'type': 'SECONDARY', 'title': 'PR-PCSS Rating for the Target and Non-target Buttock by Visit', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '205', 'groupId': 'OG001'}, {'value': '201', 'groupId': 'OG002'}, {'value': '205', 'groupId': 'OG003'}, {'value': '201', 'groupId': 'OG004'}, {'value': '205', 'groupId': 'OG005'}, {'value': '201', 'groupId': 'OG006'}, {'value': '205', 'groupId': 'OG007'}, {'value': '201', 'groupId': 'OG008'}, {'value': '205', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'Day 1: CCH', 'description': 'Baseline (Day 1) for CCH Treated Group'}, {'id': 'OG001', 'title': 'Day 1: Placebo', 'description': 'Baseline (Day 1) for Placebo Group'}, {'id': 'OG002', 'title': 'Day 22: CCH', 'description': 'Day 22 for CCH Treated Group'}, {'id': 'OG003', 'title': 'Day 22: Placebo', 'description': 'Day 22 for Placebo Group'}, {'id': 'OG004', 'title': 'Day 43: CCH', 'description': 'Day 43 for CCH Treated Group'}, {'id': 'OG005', 'title': 'Day 43: Placebo', 'description': 'Day 43 for Placebo Group'}, {'id': 'OG006', 'title': 'Day 71: CCH', 'description': 'Day 71 for CCH Treated Group'}, {'id': 'OG007', 'title': 'Day 71: Placebo', 'description': 'Day 71 for Placebo Group'}, {'id': 'OG008', 'title': 'Day 71: CCH (LOCF)', 'description': 'Day 71 for CCH Treated Group (Last observation carried forward)'}, {'id': 'OG009', 'title': 'Day 71: Placebo (LOCF)', 'description': 'Day 71 for Placebo Group (Last observation carried forward)'}], 'classes': [{'title': 'Target Buttock Rating', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '205', 'groupId': 'OG001'}, {'value': '187', 'groupId': 'OG002'}, {'value': '202', 'groupId': 'OG003'}, {'value': '188', 'groupId': 'OG004'}, {'value': '195', 'groupId': 'OG005'}, {'value': '184', 'groupId': 'OG006'}, {'value': '189', 'groupId': 'OG007'}, {'value': '201', 'groupId': 'OG008'}, {'value': '205', 'groupId': 'OG009'}]}], 'categories': [{'title': 'None (0)', 'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '2', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '2', 'groupId': 'OG009'}]}, {'title': 'Almost None (1)', 'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '13', 'groupId': 'OG004'}, {'value': '4', 'groupId': 'OG005'}, {'value': '25', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}, {'value': '25', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}, {'title': 'Mild (2)', 'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '29', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '50', 'groupId': 'OG004'}, {'value': '24', 'groupId': 'OG005'}, {'value': '54', 'groupId': 'OG006'}, {'value': '38', 'groupId': 'OG007'}, {'value': '58', 'groupId': 'OG008'}, {'value': '40', 'groupId': 'OG009'}]}, {'title': 'Moderate (3)', 'measurements': [{'value': '84', 'groupId': 'OG000'}, {'value': '82', 'groupId': 'OG001'}, {'value': '79', 'groupId': 'OG002'}, {'value': '95', 'groupId': 'OG003'}, {'value': '75', 'groupId': 'OG004'}, {'value': '95', 'groupId': 'OG005'}, {'value': '65', 'groupId': 'OG006'}, {'value': '77', 'groupId': 'OG007'}, {'value': '72', 'groupId': 'OG008'}, {'value': '81', 'groupId': 'OG009'}]}, {'title': 'Severe (4)', 'measurements': [{'value': '117', 'groupId': 'OG000'}, {'value': '123', 'groupId': 'OG001'}, {'value': '78', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '50', 'groupId': 'OG004'}, {'value': '71', 'groupId': 'OG005'}, {'value': '40', 'groupId': 'OG006'}, {'value': '67', 'groupId': 'OG007'}, {'value': '46', 'groupId': 'OG008'}, {'value': '77', 'groupId': 'OG009'}]}]}, {'title': 'Nontarget Buttock Rating', 'denoms': [{'units': 'Participants', 'counts': [{'value': '201', 'groupId': 'OG000'}, {'value': '205', 'groupId': 'OG001'}, {'value': '187', 'groupId': 'OG002'}, {'value': '202', 'groupId': 'OG003'}, {'value': '188', 'groupId': 'OG004'}, {'value': '195', 'groupId': 'OG005'}, {'value': '184', 'groupId': 'OG006'}, {'value': '190', 'groupId': 'OG007'}, {'value': '201', 'groupId': 'OG008'}, {'value': '205', 'groupId': 'OG009'}]}], 'categories': [{'title': 'None (0)', 'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '2', 'groupId': 'OG007'}, {'value': '1', 'groupId': 'OG008'}, {'value': '2', 'groupId': 'OG009'}]}, {'title': 'Almost None (1)', 'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '12', 'groupId': 'OG004'}, {'value': '4', 'groupId': 'OG005'}, {'value': '20', 'groupId': 'OG006'}, {'value': '7', 'groupId': 'OG007'}, {'value': '21', 'groupId': 'OG008'}, {'value': '7', 'groupId': 'OG009'}]}, {'title': 'Mild (2)', 'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '50', 'groupId': 'OG004'}, {'value': '33', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '34', 'groupId': 'OG007'}, {'value': '59', 'groupId': 'OG008'}, {'value': '35', 'groupId': 'OG009'}]}, {'title': 'Moderate (3)', 'measurements': [{'value': '81', 'groupId': 'OG000'}, {'value': '83', 'groupId': 'OG001'}, {'value': '81', 'groupId': 'OG002'}, {'value': '89', 'groupId': 'OG003'}, {'value': '80', 'groupId': 'OG004'}, {'value': '82', 'groupId': 'OG005'}, {'value': '63', 'groupId': 'OG006'}, {'value': '88', 'groupId': 'OG007'}, {'value': '70', 'groupId': 'OG008'}, {'value': '93', 'groupId': 'OG009'}]}, {'title': 'Severe (4)', 'measurements': [{'value': '120', 'groupId': 'OG000'}, {'value': '122', 'groupId': 'OG001'}, {'value': '77', 'groupId': 'OG002'}, {'value': '104', 'groupId': 'OG003'}, {'value': '45', 'groupId': 'OG004'}, {'value': '75', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}, {'value': '59', 'groupId': 'OG007'}, {'value': '50', 'groupId': 'OG008'}, {'value': '68', 'groupId': 'OG009'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 1 to Day 71', 'description': 'The Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) is a 5-level photonumeric scale used by the patient (participant) to assess the severity of the participant\'s cellulite. The scale ratings range from "0" (None) to "4" (Severe).', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT Population includes all ITT participants with a baseline and at least 1 post-injection evaluation of both the CR-PCSS and PR-PCSS for both the target and nontarget buttocks. All secondary and supportive efficacy evaluations were based on the mITT Population.'}, {'type': 'SECONDARY', 'title': 'Subjects Satisfaction With Cellulite Treatment at Day 71', 'denoms': [{'units': 'Participants', 'counts': [{'value': '184', 'groupId': 'OG000'}, {'value': '190', 'groupId': 'OG001'}, {'value': '195', 'groupId': 'OG002'}, {'value': '191', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Day 71: CCH', 'description': 'CCH'}, {'id': 'OG001', 'title': 'Day 71: Placebo', 'description': 'Placebo'}, {'id': 'OG002', 'title': 'Day 71: CCH (LOCF)', 'description': 'Last Observation Carried Forward - CCH'}, {'id': 'OG003', 'title': 'Day 71: Placebo (LOCF)', 'description': 'Last Observation Carried Forward - Placebo'}], 'classes': [{'categories': [{'title': 'Very Satisfied (+2)', 'measurements': [{'value': '24', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '24', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}]}, {'title': 'Satisfied (+1)', 'measurements': [{'value': '76', 'groupId': 'OG000'}, {'value': '42', 'groupId': 'OG001'}, {'value': '80', 'groupId': 'OG002'}, {'value': '42', 'groupId': 'OG003'}]}, {'title': 'Neither Satisfied Nor Dissatisfied (0)', 'measurements': [{'value': '46', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '56', 'groupId': 'OG003'}]}, {'title': 'Dissatisfied (-1)', 'measurements': [{'value': '23', 'groupId': 'OG000'}, {'value': '42', 'groupId': 'OG001'}, {'value': '23', 'groupId': 'OG002'}, {'value': '42', 'groupId': 'OG003'}]}, {'title': 'Very Dissatisfied (-2)', 'measurements': [{'value': '15', 'groupId': 'OG000'}, {'value': '43', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}, {'value': '44', 'groupId': 'OG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 71', 'description': 'A 1-level Subject Satisfaction responder is defined as a participant who is at least Satisfied (Satisfied \\[+1\\], or Very Satisfied \\[+2\\]) with the appearance of the cellulite on her buttocks at the Day 71 visit. A positive change indicates an improvement in cellulite.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT Population includes all ITT participants with a baseline and at least 1 post-injection evaluation of both the CR-PCSS and PR-PCSS for both the target and nontarget buttocks. All secondary and supportive efficacy evaluations were based on the mITT Population.'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Serum Antibody Positivity by Visit', 'denoms': [{'units': 'Participants', 'counts': [{'value': '209', 'groupId': 'OG000'}, {'value': '212', 'groupId': 'OG001'}, {'value': '209', 'groupId': 'OG002'}, {'value': '212', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Anti-AUX-I: CCH', 'description': 'CCH'}, {'id': 'OG001', 'title': 'Anti-AUX-I: Placebo', 'description': 'Placebo'}, {'id': 'OG002', 'title': 'Anti-AUX-II: CCH', 'description': 'CCH'}, {'id': 'OG003', 'title': 'Anti-AUX-II: Placebo', 'description': 'Placebo'}], 'classes': [{'title': 'Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '209', 'groupId': 'OG000'}, {'value': '212', 'groupId': 'OG001'}, {'value': '209', 'groupId': 'OG002'}, {'value': '212', 'groupId': 'OG003'}]}], 'categories': [{'title': 'Seropositive', 'measurements': [{'value': '12', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}, {'title': 'Seronegative', 'measurements': [{'value': '197', 'groupId': 'OG000'}, {'value': '207', 'groupId': 'OG001'}, {'value': '198', 'groupId': 'OG002'}, {'value': '203', 'groupId': 'OG003'}]}]}, {'title': 'Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '187', 'groupId': 'OG000'}, {'value': '200', 'groupId': 'OG001'}, {'value': '187', 'groupId': 'OG002'}, {'value': '200', 'groupId': 'OG003'}]}], 'categories': [{'title': 'Seropositive', 'measurements': [{'value': '97', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '49', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}, {'title': 'Seronegative', 'measurements': [{'value': '90', 'groupId': 'OG000'}, {'value': '195', 'groupId': 'OG001'}, {'value': '138', 'groupId': 'OG002'}, {'value': '191', 'groupId': 'OG003'}]}]}, {'title': 'Day 43', 'denoms': [{'units': 'Participants', 'counts': [{'value': '188', 'groupId': 'OG000'}, {'value': '194', 'groupId': 'OG001'}, {'value': '188', 'groupId': 'OG002'}, {'value': '194', 'groupId': 'OG003'}]}], 'categories': [{'title': 'Seropositive', 'measurements': [{'value': '186', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '180', 'groupId': 'OG002'}, {'value': '10', 'groupId': 'OG003'}]}, {'title': 'Seronegative', 'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '188', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '184', 'groupId': 'OG003'}]}]}, {'title': 'Day 71', 'denoms': [{'units': 'Participants', 'counts': [{'value': '185', 'groupId': 'OG000'}, {'value': '192', 'groupId': 'OG001'}, {'value': '185', 'groupId': 'OG002'}, {'value': '192', 'groupId': 'OG003'}]}], 'categories': [{'title': 'Seropositive', 'measurements': [{'value': '185', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '185', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}]}, {'title': 'Seronegative', 'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '182', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '180', 'groupId': 'OG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 1 - Day 71', 'description': 'Percent of participants that are seropositive. Percentages were based on the number of subjects who had immunogenicity lab samples analyzed at the visit.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population includes all participants who received at least 1 dose of CCH in this study. All safety parameters were summarized based on this population.'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Overall Antibody Titer Levels by Visit', 'denoms': [{'units': 'Participants', 'counts': [{'value': '209', 'groupId': 'OG000'}, {'value': '212', 'groupId': 'OG001'}, {'value': '209', 'groupId': 'OG002'}, {'value': '212', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Anit-AUX-I: CCH', 'description': 'CCH'}, {'id': 'OG001', 'title': 'Anti-AUX-I: Placebo', 'description': 'Placebo'}, {'id': 'OG002', 'title': 'Anti-AUX-II: CCH', 'description': 'CCH'}, {'id': 'OG003', 'title': 'Anti-AUX-II: Placebo', 'description': 'Placebo'}], 'classes': [{'title': 'Day 1 positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '4.396', 'spread': '2.2644', 'groupId': 'OG000'}, {'value': '3.682', 'spread': '2.2514', 'groupId': 'OG001'}, {'value': '4.366', 'spread': '2.1658', 'groupId': 'OG002'}, {'value': '2.478', 'spread': '1.6280', 'groupId': 'OG003'}]}]}, {'title': 'Day 22 positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '97', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '49', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '2.561', 'spread': '1.7812', 'groupId': 'OG000'}, {'value': '3.428', 'spread': '2.3377', 'groupId': 'OG001'}, {'value': '2.599', 'spread': '2.1305', 'groupId': 'OG002'}, {'value': '2.693', 'spread': '1.7244', 'groupId': 'OG003'}]}]}, {'title': 'Day 43 positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '186', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '180', 'groupId': 'OG002'}, {'value': '10', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '4.639', 'spread': '0.9961', 'groupId': 'OG000'}, {'value': '2.597', 'spread': '1.5802', 'groupId': 'OG001'}, {'value': '3.706', 'spread': '1.2138', 'groupId': 'OG002'}, {'value': '2.052', 'spread': '1.3049', 'groupId': 'OG003'}]}]}, {'title': 'Day 71 positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '185', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '185', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '6.011', 'spread': '0.6758', 'groupId': 'OG000'}, {'value': '1.845', 'spread': '1.3931', 'groupId': 'OG001'}, {'value': '5.266', 'spread': '0.7549', 'groupId': 'OG002'}, {'value': '1.927', 'spread': '1.3274', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 - Day 71', 'description': 'Descriptive statistics were based on log10 transformation of titer levels. Titer levels were imputed as 10 before the transformation if the reported level is "\\<10". Only seropositive participants are summarized.', 'unitOfMeasure': 'log 10 titer', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population includes all participants who received at least 1 dose of CCH in this study. All safety parameters were summarized based on this population.'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Presence of Neutralizing Antibody (Seropositivity) at Day 71 (LOCF) by Antidrug Antibody Log Titer Quartiles', 'denoms': [{'units': 'Participants', 'counts': [{'value': '24', 'groupId': 'OG000'}, {'value': '24', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CCH: Q1', 'description': 'Quartile 1'}, {'id': 'OG001', 'title': 'CCH: Q4', 'description': 'Quartile 4'}, {'id': 'OG002', 'title': 'CCH: Total', 'description': 'Total'}], 'classes': [{'title': 'Neutralizing AUX-I Antibody', 'denoms': [{'units': 'Participants', 'counts': [{'value': '24', 'groupId': 'OG000'}, {'value': '24', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}], 'categories': [{'title': 'Negative', 'measurements': [{'value': '16', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}]}, {'title': 'Positive', 'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '24', 'groupId': 'OG001'}, {'value': '32', 'groupId': 'OG002'}]}]}, {'title': 'Neutralizing AUX-II Antibody', 'denoms': [{'units': 'Participants', 'counts': [{'value': '23', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}, {'value': '46', 'groupId': 'OG002'}]}], 'categories': [{'title': 'Negative', 'measurements': [{'value': '10', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}, {'title': 'Positive', 'measurements': [{'value': '13', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}, {'value': '36', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 71', 'description': 'Q1 and Q4 are based on the ADA titer levels.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population includes all participants who received at least 1 dose of CCH in this study. All safety parameters were summarized based on this population.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Collagenase Clostridium Histolyticum (CCH)', 'description': 'CCH 0.84 mg/Buttock 1.68 mg Total Dose'}, {'id': 'FG001', 'title': 'Placebo', 'description': 'Placebo-control'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '210'}, {'groupId': 'FG001', 'numSubjects': '213'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '186'}, {'groupId': 'FG001', 'numSubjects': '192'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '24'}, {'groupId': 'FG001', 'numSubjects': '21'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '11'}, {'groupId': 'FG001', 'numSubjects': '10'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '9'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '9'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'Administrative', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '210', 'groupId': 'BG000'}, {'value': '213', 'groupId': 'BG001'}, {'value': '423', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Collagenase Clostridium Histolyticum (CCH)', 'description': 'CCH 0.84 mg/Buttock 1.68 mg Total Dose'}, {'id': 'BG001', 'title': 'Placebo', 'description': 'Placebo-control'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '210', 'groupId': 'BG000'}, {'value': '213', 'groupId': 'BG001'}, {'value': '423', 'groupId': 'BG002'}]}], 'categories': [{'measurements': [{'value': '47.9', 'spread': '10.33', 'groupId': 'BG000'}, {'value': '45.8', 'spread': '9.84', 'groupId': 'BG001'}, {'value': '46.9', 'spread': '10.13', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '210', 'groupId': 'BG000'}, {'value': '213', 'groupId': 'BG001'}, {'value': '423', 'groupId': 'BG002'}]}], 'categories': [{'title': 'Female', 'measurements': [{'value': '210', 'groupId': 'BG000'}, {'value': '213', 'groupId': 'BG001'}, {'value': '423', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '210', 'groupId': 'BG000'}, {'value': '213', 'groupId': 'BG001'}, {'value': '423', 'groupId': 'BG002'}]}], 'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '31', 'groupId': 'BG000'}, {'value': '41', 'groupId': 'BG001'}, {'value': '72', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '179', 'groupId': 'BG000'}, {'value': '172', 'groupId': 'BG001'}, {'value': '351', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '210', 'groupId': 'BG000'}, {'value': '213', 'groupId': 'BG001'}, {'value': '423', 'groupId': 'BG002'}]}], 'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '47', 'groupId': 'BG000'}, {'value': '43', 'groupId': 'BG001'}, {'value': '90', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '157', 'groupId': 'BG000'}, {'value': '161', 'groupId': 'BG001'}, {'value': '318', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Body Mass Index (BMI)', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '210', 'groupId': 'BG000'}, {'value': '212', 'groupId': 'BG001'}, {'value': '422', 'groupId': 'BG002'}]}], 'categories': [{'measurements': [{'value': '31.04', 'spread': '7.358', 'groupId': 'BG000'}, {'value': '30.97', 'spread': '6.856', 'groupId': 'BG001'}, {'value': '31.00', 'spread': '7.102', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'kg/m^2', 'dispersionType': 'STANDARD_DEVIATION', 'populationDescription': 'Standard deviation for BMI group categories are based on total number of participants with non-missing BMI values.'}, {'title': 'Skin Category (Fitzpatrick Scale)', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '210', 'groupId': 'BG000'}, {'value': '213', 'groupId': 'BG001'}, {'value': '423', 'groupId': 'BG002'}]}], 'categories': [{'title': 'I (Pale White)', 'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}]}, {'title': 'II (Fair)', 'measurements': [{'value': '50', 'groupId': 'BG000'}, {'value': '48', 'groupId': 'BG001'}, {'value': '98', 'groupId': 'BG002'}]}, {'title': 'III (Darker White)', 'measurements': [{'value': '69', 'groupId': 'BG000'}, {'value': '75', 'groupId': 'BG001'}, {'value': '144', 'groupId': 'BG002'}]}, {'title': 'IV (Light Brown)', 'measurements': [{'value': '40', 'groupId': 'BG000'}, {'value': '35', 'groupId': 'BG001'}, {'value': '75', 'groupId': 'BG002'}]}, {'title': 'V (Brown)', 'measurements': [{'value': '33', 'groupId': 'BG000'}, {'value': '27', 'groupId': 'BG001'}, {'value': '60', 'groupId': 'BG002'}]}, {'title': 'VI (Dark Brown)', 'measurements': [{'value': '13', 'groupId': 'BG000'}, {'value': '24', 'groupId': 'BG001'}, {'value': '37', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2018-06-05', 'size': 8705460, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2020-08-05T16:23', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 423}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2018-02-05', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-09', 'dispFirstSubmitDate': '2019-09-26', 'completionDateStruct': {'date': '2018-09-26', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-09-15', 'studyFirstSubmitDate': '2018-02-04', 'dispFirstSubmitQcDate': '2020-09-15', 'resultsFirstSubmitDate': '2020-08-05', 'studyFirstSubmitQcDate': '2018-02-05', 'dispFirstPostDateStruct': {'date': '2020-10-08', 'type': 'ACTUAL'}, 'lastUpdatePostDateStruct': {'date': '2020-10-08', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2020-09-15', 'studyFirstPostDateStruct': {'date': '2018-02-12', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2020-10-08', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-09-26', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Serum Antibody Positivity by Visit', 'timeFrame': 'Day 1 - Day 71', 'description': 'Percent of participants that are seropositive. Percentages were based on the number of subjects who had immunogenicity lab samples analyzed at the visit.'}, {'measure': 'Overall Antibody Titer Levels by Visit', 'timeFrame': 'Day 1 - Day 71', 'description': 'Descriptive statistics were based on log10 transformation of titer levels. Titer levels were imputed as 10 before the transformation if the reported level is "\\<10". Only seropositive participants are summarized.'}, {'measure': 'Presence of Neutralizing Antibody (Seropositivity) at Day 71 (LOCF) by Antidrug Antibody Log Titer Quartiles', 'timeFrame': 'Day 71', 'description': 'Q1 and Q4 are based on the ADA titer levels.'}], 'primaryOutcomes': [{'measure': '2-level Composite Responders for the Target Buttock', 'timeFrame': 'Day 71', 'description': 'Number of of 2-level Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) / Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) composite responders in the target buttock at Day 71. CR-PCSS and PR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). A participant who missed one or two assessments of CR-PCSS and PR-PCSS at Day 71 was defined as a non-responder. A 2-level composite responder is defined as a participant with an improvement from baseline of at least 2-levels of severity in the CR-PCSS and an improvement from baseline of at least 2-levels of severity in the PR-PCSS of the target buttock.'}], 'secondaryOutcomes': [{'measure': '1-level PR-PCSS Responders of the Target Buttock', 'timeFrame': 'Day 71', 'description': 'Improvement in cellulite severity of the Target Buttock from baseline of at least 1-level of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS). PR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe).'}, {'measure': '2-level PR-PCSS Responders of the Target Buttock', 'timeFrame': 'Day 71', 'description': 'Improvement in cellulite severity of the Target Buttock from baseline of at least 2-level of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS). PR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe).'}, {'measure': '1-level Composite Responders of the Target Buttock', 'timeFrame': 'Day 71', 'description': 'Improvement in cellulite severity of the Target Buttock from baseline of at least 1-level of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) / Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS). PR-PCSS and CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe).'}, {'measure': '2-level Composite Responder of the Non-target Buttock', 'timeFrame': 'Day 71', 'description': 'Improvement in cellulite severity of the Non-target Buttock from baseline of at least 2-levels of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) / Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS). PR-PCSS and CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe).'}, {'measure': '1-level SSRS Responders', 'timeFrame': 'Day 71', 'description': 'Subject Self-Rating Scale (SSRS) is a measure that assesses participant satisfaction with appearance in association with cellulite on the buttocks using whole numbers on a 7-level scale that ranges from "0" (Extremely Dissatisfied) to "6" (Extremely Satisfied). A 1-level SSRS responder is defined as a participant who is at least slightly satisfied (Slightly Satisfied \\[4\\], Very Satisfied \\[5\\], or Extremely Satisfied \\[6\\]) with the appearance of the cellulite on her buttocks at Day 71.'}, {'measure': 'Change From Baseline in PR-CIS Total Score', 'timeFrame': '71 Days', 'description': 'Patient Reported Cellulite Impact Scale (PR-CIS) is a 6-item static questionnaire, each item is answered by a participant on a 11-level numerical rating scale that ranges from "0" (Not at all) to "10" (Extremely). The PR-CIS total score is the sum of individual item scores and can range from "0" to "60" with higher numbers reflecting a more negative impact from the cellulite. A responder was defined as a participant with a reduction in the PR-CIS total score of at least 12 from baseline at an evaluation time point. A negative change from baseline indicates an improvement in cellulite severity.'}, {'measure': '1-level S-GAIS Responders of Target Buttock', 'timeFrame': 'Day 71', 'description': 'Subject Global Aesthetic Improvement Scale (S-GAIS) is a measure that assesses participant rating of cellulite appearance after treatment. This scale has 7-levels ranging from "+3" (Very Much Improved) to "-3" (Very Much Worse). Responders are defined as participants with at least ≥ 1-level improvement (Improved, Much Improved or Very Much Improved) in S-GAIS assessment of the Target Buttock.'}, {'measure': '2-level S-GAIS Responders of Target Buttock', 'timeFrame': 'Day 71', 'description': 'Subject Global Aesthetic Improvement Scale (S-GAIS) is a measure that assesses participant rating of cellulite appearance after treatment. This scale has 7-levels ranging from "+3" (Very Much Improved) to "-3" (Very Much Worse). Responders are defined as participants with at least ≥ 2-level improvement (Much Improved or Very Much Improved) in S-GAIS assessment of the Target Buttock.'}, {'measure': 'PR-PCSS Rating for the Target and Non-target Buttock by Visit', 'timeFrame': 'Day 1 to Day 71', 'description': 'The Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) is a 5-level photonumeric scale used by the patient (participant) to assess the severity of the participant\'s cellulite. The scale ratings range from "0" (None) to "4" (Severe).'}, {'measure': 'Subjects Satisfaction With Cellulite Treatment at Day 71', 'timeFrame': 'Day 71', 'description': 'A 1-level Subject Satisfaction responder is defined as a participant who is at least Satisfied (Satisfied \\[+1\\], or Very Satisfied \\[+2\\]) with the appearance of the cellulite on her buttocks at the Day 71 visit. A positive change indicates an improvement in cellulite.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Edematous Fibrosclerotic Panniculopathy (Cellulite)']}, 'referencesModule': {'references': [{'pmid': '33840781', 'type': 'DERIVED', 'citation': 'Kaufman-Janette J, Joseph JH, Kaminer MS, Clark J, Fabi SG, Gold MH, Goldman MP, Katz BE, Peddy K, Schlessinger J, Young VL, Davis M, Hurley D, Liu G, McLane MP, Vijayan S, Bass LS. Collagenase Clostridium Histolyticum-aaes for the Treatment of Cellulite in Women: Results From Two Phase 3 Randomized, Placebo-Controlled Trials. Dermatol Surg. 2021 May 1;47(5):649-656. doi: 10.1097/DSS.0000000000002952.'}]}, 'descriptionModule': {'briefSummary': 'Subjects will be screened for study eligibility within 14 days prior to enrolling in this study. Subjects with 2 treatment areas (bilateral buttocks) with moderate or severe levels of cellulite as independently assessed by the subject using the Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS) and by the Investigator using the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) will be eligible. The eligibility of the buttocks will be confirmed on Day 1. Once the eligibility of the buttocks is confirmed, subjects will be randomly assigned to a treatment group (EN3835 0.84 mg per buttock or placebo) in a 1:1 ratio within an investigational site. Each subject will receive a treatment course which consists of up to 3 treatment visits (sessions), separated by 21 days (ie, Days 1, 22, and 43). Each treatment visit will consist of 12 injections (0.3 mL per injection of EN3835 0.07 mg/injection or placebo; 0.84 mg in 3.6 mL per buttock) in each of the two buttocks for a total volume of 7.2 mL (1.68 mg). Selection of dimples to be treated in the buttocks will be at the discretion of the Investigator. End of study will occur at study day 71.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Voluntarily sign and date an informed consent agreement\n2. Be a female ≥18 years of age\n3. At Screening visit, have 2 bilateral buttocks with each buttock having:\n\n 1. a score of 3 or 4 (moderate or severe) as reported by the subject (PR-PCSS), and\n 2. a score of 3 or 4 (moderate or severe) as reported by the Investigator (CR-PCSS)\n4. At Day 1 visit, have 2 bilateral buttocks with each buttock having:\n\n 1. a score of 3 or 4 (moderate or severe) as reported by the subject (PR-PCSS), and\n 2. a score of 3 or 4 (moderate or severe) as reported by the Investigator (CR-PCSS)\n5. Be willing to apply sunscreen to the buttocks before each exposure to the sun while participating in the study (ie, Screening through end of study)\n6. Be judged to be in good health, based upon the results of a medical history, physical examination, and laboratory profile at Screening\n7. Have a negative serum pregnancy test at Screening and a negative urine pregnancy test before injection of study drug and be using a stable and effective contraception method (eg, abstinence, intrauterine device \\[IUD\\], hormonal \\[estrogen/progestin\\] contraceptives, or double barrier method) for at least 1 menstrual cycle prior to study enrollment and for the duration of the study; or be menopausal defined as 12 months of amenorrhea in the absence of other biological or physiological causes, as determined by the Investigator; or post-menopausal for at least 1 year; or be surgically sterile\n8. Be willing and able to cooperate with the requirements of the study\n9. Be able to read, complete and understand the patient-reported outcomes rating instruments in English\n\nExclusion Criteria:\n\n1. Has any of the following systemic conditions:\n\n 1. Coagulation disorder\n 2. Evidence or history of malignancy (other than excised basal-cell carcinoma) unless there has been no recurrence in at least 5 years\n 3. History of keloidal scarring or abnormal wound healing\n 4. Concurrent diseases or conditions that might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the subject's well-being. Any questions about concurrent diseases should be discussed with the Medical Monitor\n 5. Evidence of clinically significant abnormalities on physical examination, vital signs, electrocardiogram (ECG), or clinical laboratory values\n2. Has any of the following local conditions in the areas to be treated:\n\n 1. History of lower extremity thrombosis or post-thrombosis syndrome\n 2. Vascular disorder (eg, varicose veins, telangiectasia) in area to be treated\n 3. Inflammation or active infection\n 4. Severe skin laxity, flaccidity, and/or sagging\n 5. Active cutaneous alteration including rash, eczema, psoriasis, or skin cancer\n 6. Has a tattoo and/or a mole located within 2 cm of the site of injection\n3. Requires the following concomitant medications before or during participation in the trial:\n\n a. Anticoagulant or antiplatelet medication or has received anticoagulant or antiplatelet medication (except for ≤150 mg aspirin daily) within 7 days before injection of study drug\n4. Has used any of the following for the treatment of EFP on a buttock within the timelines identified below or intends to use any of the following at any time during the course of the study:\n\n 1. Liposuction in a buttock during the 12-month period before injection of study drug\n 2. Injections (eg, mesotherapy); radiofrequency device treatments; laser treatment; buttock implant treatment; cryolipolysis; or surgery (including subcision and/or powered subcision) within a buttock during the 12-month period before injection of study drug\n 3. Any investigational treatment for EFP on a buttock during the 12-month period before the injection of study drug\n 4. Endermologie or similar treatments within a buttock during the 6-month period before injection of study drug\n 5. Massage therapy within a buttock during the 3-month period before injection of study drug\n 6. Creams (eg, Celluvera™, TriLastin®) and/or home therapies to prevent or mitigate EFP within a buttock during the 2-week period before injection of study drug\n5. Is presently nursing or providing breast milk\n6. Intends to become pregnant during the study\n7. Intends to initiate an intensive sport or exercise program during the study\n8. Intends to initiate a weight reduction program during the study\n9. Intends to use tanning spray or tanning booths during the study\n10. Has received an investigational drug or treatment within 30 days before injection of study drug\n11. Has a known systemic allergy to collagenase or any other excipient of study drug\n12. Has received any collagenase treatments at any time prior to treatment\n13. Was a subject in a previous cellulite clinical trial of CCH: AUX-CC-830, AUX-CC-831, EN3835-102, EN3835-104, EN3835-201, EN3835-202, and/or EN3835-205\n14. Any other condition(s) that, in the Investigator's opinion, might indicate the subject to be unsuitable for the study"}, 'identificationModule': {'nctId': 'NCT03428750', 'acronym': 'RELEASE-1', 'briefTitle': 'Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women', 'organization': {'class': 'INDUSTRY', 'fullName': 'Endo Pharmaceuticals'}, 'officialTitle': 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy (Cellulite)', 'orgStudyIdInfo': {'id': 'EN3835-302'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'EN3835 Active', 'description': 'EN3835 0.84mg (Collagenase Clostridium Histolyticum)', 'interventionNames': ['Biological: EN3835']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'interventionNames': ['Biological: Placebo']}], 'interventions': [{'name': 'EN3835', 'type': 'BIOLOGICAL', 'description': 'Collagenase clostridium histolyticum', 'armGroupLabels': ['EN3835 Active']}, {'name': 'Placebo', 'type': 'BIOLOGICAL', 'description': 'Placebo', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85258', 'city': 'Scottsdale', 'state': 'Arizona', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #1', 'geoPoint': {'lat': 33.50921, 'lon': -111.89903}}, {'zip': '92024', 'city': 'Encinitas', 'state': 'California', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #2', 'geoPoint': {'lat': 33.03699, 'lon': -117.29198}}, {'zip': '90806', 'city': 'Long Beach', 'state': 'California', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #3', 'geoPoint': {'lat': 33.76696, 'lon': -118.18923}}, {'zip': '90025', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #4', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '92056', 'city': 'Oceanside', 'state': 'California', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #5', 'geoPoint': {'lat': 33.19587, 'lon': -117.37948}}, {'zip': '92121', 'city': 'San Diego', 'state': 'California', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #6', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '33486', 'city': 'Boca Raton', 'state': 'Florida', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #7', 'geoPoint': {'lat': 26.35869, 'lon': -80.0831}}, {'zip': '33770', 'city': 'Largo', 'state': 'Florida', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #8', 'geoPoint': {'lat': 27.90979, 'lon': -82.78842}}, {'zip': '33185', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #9', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '30078', 'city': 'Snellville', 'state': 'Georgia', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #10', 'geoPoint': {'lat': 33.85733, 'lon': -84.01991}}, {'zip': '60654', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #11', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '70115', 'city': 'New Orleans', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #12', 'geoPoint': {'lat': 29.95465, 'lon': -90.07507}}, {'zip': '02467', 'city': 'Chestnut Hill', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #13', 'geoPoint': {'lat': 42.33065, 'lon': -71.16616}}, {'zip': '02169', 'city': 'Quincy', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #14', 'geoPoint': {'lat': 42.25288, 'lon': -71.00227}}, {'zip': '55432', 'city': 'Fridley', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #15', 'geoPoint': {'lat': 45.08608, 'lon': -93.26328}}, {'zip': '63090', 'city': 'Washington', 'state': 'Missouri', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #16', 'geoPoint': {'lat': 38.55811, 'lon': -91.01209}}, {'zip': '68144', 'city': 'Omaha', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #17', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '10549', 'city': 'Mount Kisco', 'state': 'New York', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #18', 'geoPoint': {'lat': 41.20426, 'lon': -73.72708}}, {'zip': '10022', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #21', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10065', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #19', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10075', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #20', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '45249', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #22', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '77056', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #23', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '78660', 'city': 'Pflugerville', 'state': 'Texas', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #24', 'geoPoint': {'lat': 30.43937, 'lon': -97.62}}, {'zip': '77497', 'city': 'Sugar Land', 'state': 'Texas', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #25', 'geoPoint': {'lat': 29.61968, 'lon': -95.63495}}, {'zip': '22911', 'city': 'Charlottesville', 'state': 'Virginia', 'country': 'United States', 'facility': 'Endo Clinical Trial Site #26', 'geoPoint': {'lat': 38.02931, 'lon': -78.47668}}], 'overallOfficials': [{'name': 'Michael McLane', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Endo Pharmaceuticals'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Endo Pharmaceuticals', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}